• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » 2009 Annual Life Sciences Venture Capital Outlook Event

2009 Annual Life Sciences Venture Capital Outlook Event

March 11, 2009 By David Spenciner

In a post-event haze fueled by rice and curry chicken (the 2009 Annual Life Sciences Venture Capital Outlook Event was held by The Indus Entrepreneurs), I can conclude that medtech in Massachusetts continues to be a great place to innovate and invest, but as entrepreneurs we need to pause to let the markets settle down a bit before raising more funding.

About 100 venture capitalists, entrepreneurs, and students sat down March 11 in a Harvard Business School lecture room for two presentations by local MedTech entrepreneurs.

{IMGRIGHT:85×85:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/picture-34.jpg}I thought that both Ninth Sense (nanowire diagnostic for point-of-care breast cancer detection) and Moma Therapeutics (novel hydrogel dermal filler) did a great job pitching their companies. Representatives of Canaan Partners, < a href="http://www.siemensventurecapital.com/">Siemens Venture Capital, and Galen Partners asked them some tough questions and gave their initial feedback to the presenters.

While these thoughts were directed specifically at these two particular startups, their pearls of advice are applicable to all of us entrepreneurs:

1. Pick your first application carefully and stay focused on that one application.
Make sure that the market need is there for your device and that your product actually serves that need.
2. Get your intellectual property nailed down before you start making pitches.
If you can wait until it’s granted, that’s great, but at least make sure that all of your IP has been filed and your licenses are all signed (and exclusive!).
3. Finally, consider going overseas.
There are two reasons for this: Gaining clinical experience at lower cost than staying in the US and to start shipping product and therefore gaining a revenue stream earlier.

The second part of the evening comprised four presentations by the panelists on their outlook for VC in the biotech and MedTech spaces. I could devote an entire column to each of their presentations, but here are some of the highlights:

• Roopom Banerjee (Director, Leerink Swann): The confluence of the worst capital markets since the 1930s, a closed IPO market and weak M&A market (except perhaps for a few biotechs) and a 20% decrease in VC fundraising last year has shifted the priorities of VC firms. So-called “A” companies can still find institutional funding, but firms are now prioritizing their portfolio companies over prospects and generally shifting to later stage investments (including PIPEs) to lower the risk profile of their portfolios.
• Andrew Jay (Managing Partner, Siemens Venture Capital): Medtech remains a hot area for investment due to the market’s receptiveness to innovation and the high margins. Key device markets include cardiovascular, orthopedics, neurology and cosmetics.
• Stephen Bloch (General Partner, Canaan Partners): For IPOs, the money returned to investors approximately equals the money put into these companies. M&As often provide a preferred exit due to the potential for higher multiples. Successful exits often require that entrepreneurs build real companies (with real products), meet or exceed benchmarks, be cost efficient and design their business to be an attractive near-term acquisition target.
• David Jahns (Managing Director, Galen Partners): Two things are particularly great about medtech: the strong barriers to entry provided by IP and the high margins in the marketplace. Entrepreneurs need to be patient right now and avoid raising cash unless they absolutely need to. Companies that can afford to wait a little while should find themselves in a better bargaining position.

So what do medtech entrepreneurs need to do to survive this rough patch? Everyone’s list should include protecting IP, building something that brings real value to the marketplace, staying focused on core technology and efficiently meeting milestones.

Filed Under: Uncategorized Tagged With: Venture Capital/Private Equity

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS